Shopping Cart
Remove All
Your shopping cart is currently empty
KCC-07 is a selective, potent and brain-penetrant inhibitor of methyl-CpG-binding domain protein 2(MBD2) with anticancer activity. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | In Stock | In Stock | |
| 5 mg | $68 | In Stock | In Stock | |
| 10 mg | $120 | In Stock | In Stock | |
| 25 mg | $235 | In Stock | In Stock | |
| 50 mg | $373 | In Stock | In Stock | |
| 100 mg | $556 | In Stock | In Stock | |
| 200 mg | $792 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $71 | In Stock | In Stock |
| Description | KCC-07 is a selective, potent and brain-penetrant inhibitor of methyl-CpG-binding domain protein 2(MBD2) with anticancer activity. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling. |
| In vitro | In vitro, KCC-07 treatment Medulloblastomas (MB) cells?clearly inhibited MB cell growth, consistent with induction of anti-proliferative BAI1/p53/p21 signaling |
| Cell Research | KCC-07?treatment?Medulloblastomas (MB) cells, Concentration with?10 μM and?Incubation Time with?72 hours |
| Molecular Weight | 269.32 |
| Formula | C14H11N3OS |
| Cas No. | 315702-75-1 |
| Smiles | OC1=CC=CC(NC2=NC(=CS2)C2=NC=CC=C2)=C1 |
| Relative Density. | 1.380 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 22.5 mg/mL (83.54 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.43 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.